CBIO

CRESCENT BIOPHARMA, INC. CBIO

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,908 of 2,925

Why it scores 7Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-24.84M

Quarter to Jun 30

Free cash flow

$-19.48M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$532.56M total
FMR LLC
$74.40M0.0%
BVF INC/IL
$49.48M0.0%
Fairmount Funds Management LLC
$49.46M0.0%
VR Adviser, LLC
$38.40M0.0%
Logos Global Management LP
$34.20M+293.8%
FCPM III SERVICES B.V.
$30.20M0.0%
BALYASNY ASSET MANAGEMENT L.P.
$29.93M+10.1%
Vestal Point Capital, LP
$29.34M+8.7%
Opaleye Management Inc.
$23.75M+0.5%
BlackRock, Inc.
$22.89M+999.0%
TANG CAPITAL MANAGEMENT LLC
$20.88M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$13.82M-4.2%
Boxer Capital Management, LLC
$8.17M0.0%
MILLENNIUM MANAGEMENT LLC
$7.27M+24.8%
GEODE CAPITAL MANAGEMENT, LLC
$6.92M+269.0%
JENNISON ASSOCIATES LLC
$6.81M+147.4%
RTW INVESTMENTS, LP
$6.71M0.0%
NEXTBio Capital Management LP
$6.71M0.0%
Remedium Capital Partners, LLC
$6.50M0.0%
STATE STREET CORP
$5.68M+707.8%
AMERIPRISE FINANCIAL INC
$5.45MNew
Point72 Asset Management, L.P.
$5.40M0.0%
PRICE T ROWE ASSOCIATES INC /MD/
$4.96M-9.2%
MARSHALL WACE, LLP
$3.86M+6.7%
PERCEPTIVE ADVISORS LLC
$3.72M0.0%
See all 82 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CBIO

Earnings Per Share

13fpro.ai/company/CBIO

Loading ratio trend…

CBIO key financials by period

Reported revenue, net income and operating margin by fiscal year, from CRESCENT BIOPHARMA, INC.'s annual filings on SEC EDGAR.

CRESCENT BIOPHARMA, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$10.8M$-153.9M—
FY 2023$10.0K$-36.9M—
FY 2022$75.0K$-46.7M—
FY 2021$1.2M$-63.4M—
FY 2020$10.2M$-51.0M—
FY 2016$18.5K$-31.8M—
Source: CBIO filings on SEC EDGAR →

Companies similar to CBIO

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

CBIO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About CRESCENT BIOPHARMA, INC. (CBIO): stock profile, AI score and financials

CRESCENT BIOPHARMA, INC. (CBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CBIO at 7.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,908 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.6) and revenue scale (0.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CRESCENT BIOPHARMA, INC. reports net income of $-24.8M, free cash flow of $-19.5M. Top institutional holders of CBIO by reported 13-F value include FMR, BVF, Fairmount Funds Management, based on the most recent SEC filings. CBIO trades on the Nasdaq exchange and files with the SEC under CIK 1253689. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRESCENT BIOPHARMA, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1253689 →